Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
Alfred L. Garfall(University of Pennsylvania), Ajai Chari(Icahn School of Medicine at Mount Sinai), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Jesús F. San Miguel(Clinica Universidad de Navarra), Kristy Kemmerer(Janssen (United States)), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Hareth Nahi(Karolinska University Hospital), Albert Oriol(Institut Català d'Oncologia), Arnob Banerjee(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Jennifer Smit(Janssen (United States)), Jeffrey R. Infante(Cancer Research Center), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Yusri Elsayed(Janssen (United States)), Homer Adams(Janssen (United States)), Amrita Krishnan(City of Hope)
Cited by 42
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k